Despite the unprecedented disruption and shift in priorities that COVID-19 brought to FDA’s Office of New Drugs (OND) in 2020, the office’s annual report shows it reviewed more than 320 trials for potential COVID-19 therapeutics and more than 570 drug development programs in the planning stages.